Jaguar Health Starts POC Trial of Crofelemer for Rare Pediatric Disease MVID

Jaguar Health, Inc. (Jaguar) affiliated companies Napo Pharmaceuticals (Napo) and Napo Therapeutics announced that the first patient has received a dose in the independent investigator-led POC trial of crofelemer, Jaguar's innovative plant-derived anti-diarrheal prescription medication, targeting the rare disease MVID in children. POC data produced from this research potentially in early 2025 may enable reimbursed early patient access to crofelemer for this condition in select European nations.

The study will also involve pediatric patients with SBS-IF. The study is led by Dr. Mohamad Miqdady, an esteemed authority in pediatric gastroenterology, who serves as the division chief of pediatric gastroenterology, hepatology & nutrition at Sheikh Khalifa Medical City (SKMC), a premier tertiary hospital in the UAE and the largest teaching hospital in Abu Dhabi.

"Administering the initial dose to the first participant in this unblinded study marks a significant milestone in the clinical development of crofelemer for MVID and SBS-IF—two rare, severe conditions that necessitate comprehensive parenteral nutrition and support," stated Lisa Conte, founder, president, and CEO of Jaguar.

The trial is occurring at SKMC. Autosomal recessive conditions and congenital malformations like MVID are more common in the Middle East and North Africa (MENA) area.